"Can Cell Therapeutics find a partner willing to sell pixantrone in exchange for a significant royalty payment? Maybe. Bianco is telling investors that Novartis(NVS Quote), which has an option on pixantrone, is very interested"
2. Buyout formula 1 share CTIC = 1 share NVS (Novartis) = around $40/share;
3. Novartis investors could buy NVS for 40 times less if they buy CTIC now;